Duchenne Muscular Dystrophy Therapeutics Market, Global Outlook and Forecast 2022-2028

April 2022 | 64 pages | ID: D9632E497961EN
Market Monitor Global

Abstracts

Duchenne muscular dystrophy (DMD) therapeutics helps treat genetic disorder caused due to absence of dystrophin, a protein in the body. The symptoms of the disease include weakness in the muscles of the hips, pelvic area, thighs, and shoulders, and later in the muscles of arms, legs, and trunk.

This report contains market size and forecasts of Duchenne Muscular Dystrophy Therapeutics in Global, including the following market information:

Global Duchenne Muscular Dystrophy Therapeutics Market Revenue, 2017-2022, 2023-2028, ($ millions)

Global top five companies in 2021 (%)

The global Duchenne Muscular Dystrophy Therapeutics market was valued at 989.7 million in 2021 and is projected to reach US$ 5471 million by 2028, at a CAGR of 27.7% during the forecast period.

The U.S. Market is Estimated at $ Million in 2021, While China is Forecast to Reach $ Million by 2028.

Pain Management Drugs Segment to Reach $ Million by 2028, with a % CAGR in next six years.

The global key manufacturers of Duchenne Muscular Dystrophy Therapeutics include Bristol-Myers Squibb, FibroGen (US), Italfarmaco (Italy), Marathon, NS Pharma (US), PTC Therapeutics (US), Pfizer, ReveraGen BioPharma (US) and Santhera Pharmaceuticals (Switzerland) and etc. In 2021, the global top five players have a share approximately % in terms of revenue.

MARKET MONITOR GLOBAL, INC (MMG) has surveyed the Duchenne Muscular Dystrophy Therapeutics companies, and industry experts on this industry, involving the revenue, demand, product type, recent developments and plans, industry trends, drivers, challenges, obstacles, and potential risks.

Total Market by Segment:

Global Duchenne Muscular Dystrophy Therapeutics Market, by Type, 2017-2022, 2023-2028 ($ millions)

Global Duchenne Muscular Dystrophy Therapeutics Market Segment Percentages, by Type, 2021 (%)

• Pain Management Drugs
• Corticosteroids
• Prednisolone
• Prednisone
• Deflazacort

Global Duchenne Muscular Dystrophy Therapeutics Market, by Application, 2017-2022, 2023-2028 ($ millions)

Global Duchenne Muscular Dystrophy Therapeutics Market Segment Percentages, by Application, 2021 (%)

• Hospitals
• Clinics
• Home Care

Global Duchenne Muscular Dystrophy Therapeutics Market, By Region and Country, 2017-2022, 2023-2028 ($ Millions)

Global Duchenne Muscular Dystrophy Therapeutics Market Segment Percentages, By Region and Country, 2021 (%)

• North America
• US
• Canada
• Mexico
• Europe
• Germany
• France
• U.K.
• Italy
• Russia
• Nordic Countries
• Benelux
• Rest of Europe
• Asia
• China
• Japan
• South Korea
• Southeast Asia
• India
• Rest of Asia
• South America
• Brazil
• Argentina
• Rest of South America
• Middle East & Africa
• Turkey
• Israel
• Saudi Arabia
• UAE
• Rest of Middle East & Africa

Competitor Analysis

The report also provides analysis of leading market participants including:

Key companies Duchenne Muscular Dystrophy Therapeutics revenues in global market, 2017-2022 (estimated), ($ millions)

Key companies Duchenne Muscular Dystrophy Therapeutics revenues share in global market, 2021 (%)

Further, the report presents profiles of competitors in the market, key players include:

• Bristol-Myers Squibb
• FibroGen (US)
• Italfarmaco (Italy)
• Marathon
• NS Pharma (US)
• PTC Therapeutics (US)
• Pfizer
• ReveraGen BioPharma (US)
• Santhera Pharmaceuticals (Switzerland)
• Sarepta Therapeutics (US)

Contents

1 INTRODUCTION TO RESEARCH & ANALYSIS REPORTS

1.1 Duchenne Muscular Dystrophy Therapeutics Market Definition
1.2 Market Segments
  1.2.1 Market by Type
  1.2.2 Market by Application
1.3 Global Duchenne Muscular Dystrophy Therapeutics Market Overview
1.4 Features & Benefits of This Report
1.5 Methodology & Sources of Information
  1.5.1 Research Methodology
  1.5.2 Research Process
  1.5.3 Base Year
  1.5.4 Report Assumptions & Caveats

2 GLOBAL DUCHENNE MUSCULAR DYSTROPHY THERAPEUTICS OVERALL MARKET SIZE

2.1 Global Duchenne Muscular Dystrophy Therapeutics Market Size: 2021 VS 2028
2.2 Global Duchenne Muscular Dystrophy Therapeutics Market Size, Prospects & Forecasts: 2017-2028
2.3 Key Market Trends, Opportunity, Drivers and Restraints
  2.3.1 Market Opportunities & Trends
  2.3.2 Market Drivers
  2.3.3 Market Restraints

3 COMPANY LANDSCAPE

3.1 Top Duchenne Muscular Dystrophy Therapeutics Players in Global Market
3.2 Top Global Duchenne Muscular Dystrophy Therapeutics Companies Ranked by Revenue
3.3 Global Duchenne Muscular Dystrophy Therapeutics Revenue by Companies
3.4 Top 3 and Top 5 Duchenne Muscular Dystrophy Therapeutics Companies in Global Market, by Revenue in 2021
3.5 Global Companies Duchenne Muscular Dystrophy Therapeutics Product Type
3.6 Tier 1, Tier 2 and Tier 3 Duchenne Muscular Dystrophy Therapeutics Players in Global Market
  3.6.1 List of Global Tier 1 Duchenne Muscular Dystrophy Therapeutics Companies
  3.6.2 List of Global Tier 2 and Tier 3 Duchenne Muscular Dystrophy Therapeutics Companies

4 MARKET SIGHTS BY PRODUCT

4.1 Overview
  4.1.1 by Type - Global Duchenne Muscular Dystrophy Therapeutics Market Size Markets, 2021 & 2028
  4.1.2 Pain Management Drugs
  4.1.3 Corticosteroids
  4.1.4 Prednisolone
  4.1.5 Prednisone
  4.1.6 Deflazacort
4.2 By Type - Global Duchenne Muscular Dystrophy Therapeutics Revenue & Forecasts
  4.2.1 By Type - Global Duchenne Muscular Dystrophy Therapeutics Revenue, 2017-2022
  4.2.2 By Type - Global Duchenne Muscular Dystrophy Therapeutics Revenue, 2023-2028
  4.2.3 By Type - Global Duchenne Muscular Dystrophy Therapeutics Revenue Market Share, 2017-2028

5 SIGHTS BY APPLICATION

5.1 Overview
  5.1.1 By Application - Global Duchenne Muscular Dystrophy Therapeutics Market Size, 2021 & 2028
  5.1.2 Hospitals
  5.1.3 Clinics
  5.1.4 Home Care
5.2 By Application - Global Duchenne Muscular Dystrophy Therapeutics Revenue & Forecasts
  5.2.1 By Application - Global Duchenne Muscular Dystrophy Therapeutics Revenue, 2017-2022
  5.2.2 By Application - Global Duchenne Muscular Dystrophy Therapeutics Revenue, 2023-2028
  5.2.3 By Application - Global Duchenne Muscular Dystrophy Therapeutics Revenue Market Share, 2017-2028

6 SIGHTS BY REGION

6.1 By Region - Global Duchenne Muscular Dystrophy Therapeutics Market Size, 2021 & 2028
6.2 By Region - Global Duchenne Muscular Dystrophy Therapeutics Revenue & Forecasts
  6.2.1 By Region - Global Duchenne Muscular Dystrophy Therapeutics Revenue, 2017-2022
  6.2.2 By Region - Global Duchenne Muscular Dystrophy Therapeutics Revenue, 2023-2028
  6.2.3 By Region - Global Duchenne Muscular Dystrophy Therapeutics Revenue Market Share, 2017-2028
6.3 North America
  6.3.1 By Country - North America Duchenne Muscular Dystrophy Therapeutics Revenue, 2017-2028
  6.3.2 US Duchenne Muscular Dystrophy Therapeutics Market Size, 2017-2028
  6.3.3 Canada Duchenne Muscular Dystrophy Therapeutics Market Size, 2017-2028
  6.3.4 Mexico Duchenne Muscular Dystrophy Therapeutics Market Size, 2017-2028
6.4 Europe
  6.4.1 By Country - Europe Duchenne Muscular Dystrophy Therapeutics Revenue, 2017-2028
  6.4.2 Germany Duchenne Muscular Dystrophy Therapeutics Market Size, 2017-2028
  6.4.3 France Duchenne Muscular Dystrophy Therapeutics Market Size, 2017-2028
  6.4.4 U.K. Duchenne Muscular Dystrophy Therapeutics Market Size, 2017-2028
  6.4.5 Italy Duchenne Muscular Dystrophy Therapeutics Market Size, 2017-2028
  6.4.6 Russia Duchenne Muscular Dystrophy Therapeutics Market Size, 2017-2028
  6.4.7 Nordic Countries Duchenne Muscular Dystrophy Therapeutics Market Size, 2017-2028
  6.4.8 Benelux Duchenne Muscular Dystrophy Therapeutics Market Size, 2017-2028
6.5 Asia
  6.5.1 By Region - Asia Duchenne Muscular Dystrophy Therapeutics Revenue, 2017-2028
  6.5.2 China Duchenne Muscular Dystrophy Therapeutics Market Size, 2017-2028
  6.5.3 Japan Duchenne Muscular Dystrophy Therapeutics Market Size, 2017-2028
  6.5.4 South Korea Duchenne Muscular Dystrophy Therapeutics Market Size, 2017-2028
  6.5.5 Southeast Asia Duchenne Muscular Dystrophy Therapeutics Market Size, 2017-2028
  6.5.6 India Duchenne Muscular Dystrophy Therapeutics Market Size, 2017-2028
6.6 South America
  6.6.1 By Country - South America Duchenne Muscular Dystrophy Therapeutics Revenue, 2017-2028
  6.6.2 Brazil Duchenne Muscular Dystrophy Therapeutics Market Size, 2017-2028
  6.6.3 Argentina Duchenne Muscular Dystrophy Therapeutics Market Size, 2017-2028
6.7 Middle East & Africa
  6.7.1 By Country - Middle East & Africa Duchenne Muscular Dystrophy Therapeutics Revenue, 2017-2028
  6.7.2 Turkey Duchenne Muscular Dystrophy Therapeutics Market Size, 2017-2028
  6.7.3 Israel Duchenne Muscular Dystrophy Therapeutics Market Size, 2017-2028
  6.7.4 Saudi Arabia Duchenne Muscular Dystrophy Therapeutics Market Size, 2017-2028
  6.7.5 UAE Duchenne Muscular Dystrophy Therapeutics Market Size, 2017-2028

7 PLAYERS PROFILES

7.1 Bristol-Myers Squibb
  7.1.1 Bristol-Myers Squibb Corporate Summary
  7.1.2 Bristol-Myers Squibb Business Overview
  7.1.3 Bristol-Myers Squibb Duchenne Muscular Dystrophy Therapeutics Major Product Offerings
  7.1.4 Bristol-Myers Squibb Duchenne Muscular Dystrophy Therapeutics Revenue in Global Market (2017-2022)
  7.1.5 Bristol-Myers Squibb Key News
7.2 FibroGen (US)
  7.2.1 FibroGen (US) Corporate Summary
  7.2.2 FibroGen (US) Business Overview
  7.2.3 FibroGen (US) Duchenne Muscular Dystrophy Therapeutics Major Product Offerings
  7.2.4 FibroGen (US) Duchenne Muscular Dystrophy Therapeutics Revenue in Global Market (2017-2022)
  7.2.5 FibroGen (US) Key News
7.3 Italfarmaco (Italy)
  7.3.1 Italfarmaco (Italy) Corporate Summary
  7.3.2 Italfarmaco (Italy) Business Overview
  7.3.3 Italfarmaco (Italy) Duchenne Muscular Dystrophy Therapeutics Major Product Offerings
  7.3.4 Italfarmaco (Italy) Duchenne Muscular Dystrophy Therapeutics Revenue in Global Market (2017-2022)
  7.3.5 Italfarmaco (Italy) Key News
7.4 Marathon
  7.4.1 Marathon Corporate Summary
  7.4.2 Marathon Business Overview
  7.4.3 Marathon Duchenne Muscular Dystrophy Therapeutics Major Product Offerings
  7.4.4 Marathon Duchenne Muscular Dystrophy Therapeutics Revenue in Global Market (2017-2022)
  7.4.5 Marathon Key News
7.5 NS Pharma (US)
  7.5.1 NS Pharma (US) Corporate Summary
  7.5.2 NS Pharma (US) Business Overview
  7.5.3 NS Pharma (US) Duchenne Muscular Dystrophy Therapeutics Major Product Offerings
  7.5.4 NS Pharma (US) Duchenne Muscular Dystrophy Therapeutics Revenue in Global Market (2017-2022)
  7.5.5 NS Pharma (US) Key News
7.6 PTC Therapeutics (US)
  7.6.1 PTC Therapeutics (US) Corporate Summary
  7.6.2 PTC Therapeutics (US) Business Overview
  7.6.3 PTC Therapeutics (US) Duchenne Muscular Dystrophy Therapeutics Major Product Offerings
  7.6.4 PTC Therapeutics (US) Duchenne Muscular Dystrophy Therapeutics Revenue in Global Market (2017-2022)
  7.6.5 PTC Therapeutics (US) Key News
7.7 Pfizer
  7.7.1 Pfizer Corporate Summary
  7.7.2 Pfizer Business Overview
  7.7.3 Pfizer Duchenne Muscular Dystrophy Therapeutics Major Product Offerings
  7.7.4 Pfizer Duchenne Muscular Dystrophy Therapeutics Revenue in Global Market (2017-2022)
  7.7.5 Pfizer Key News
7.8 ReveraGen BioPharma (US)
  7.8.1 ReveraGen BioPharma (US) Corporate Summary
  7.8.2 ReveraGen BioPharma (US) Business Overview
  7.8.3 ReveraGen BioPharma (US) Duchenne Muscular Dystrophy Therapeutics Major Product Offerings
  7.8.4 ReveraGen BioPharma (US) Duchenne Muscular Dystrophy Therapeutics Revenue in Global Market (2017-2022)
  7.8.5 ReveraGen BioPharma (US) Key News
7.9 Santhera Pharmaceuticals (Switzerland)
  7.9.1 Santhera Pharmaceuticals (Switzerland) Corporate Summary
  7.9.2 Santhera Pharmaceuticals (Switzerland) Business Overview
  7.9.3 Santhera Pharmaceuticals (Switzerland) Duchenne Muscular Dystrophy Therapeutics Major Product Offerings
  7.9.4 Santhera Pharmaceuticals (Switzerland) Duchenne Muscular Dystrophy Therapeutics Revenue in Global Market (2017-2022)
  7.9.5 Santhera Pharmaceuticals (Switzerland) Key News
7.10 Sarepta Therapeutics (US)
  7.10.1 Sarepta Therapeutics (US) Corporate Summary
  7.10.2 Sarepta Therapeutics (US) Business Overview
  7.10.3 Sarepta Therapeutics (US) Duchenne Muscular Dystrophy Therapeutics Major Product Offerings
  7.10.4 Sarepta Therapeutics (US) Duchenne Muscular Dystrophy Therapeutics Revenue in Global Market (2017-2022)
  7.10.5 Sarepta Therapeutics (US) Key News

8 CONCLUSION

9 APPENDIX

9.1 Note
9.2 Examples of Clients
9.3 Disclaimer

List Of Tables

LIST OF TABLES

Table 1. Duchenne Muscular Dystrophy Therapeutics Market Opportunities & Trends in Global Market
Table 2. Duchenne Muscular Dystrophy Therapeutics Market Drivers in Global Market
Table 3. Duchenne Muscular Dystrophy Therapeutics Market Restraints in Global Market
Table 4. Key Players of Duchenne Muscular Dystrophy Therapeutics in Global Market
Table 5. Top Duchenne Muscular Dystrophy Therapeutics Players in Global Market, Ranking by Revenue (2021)
Table 6. Global Duchenne Muscular Dystrophy Therapeutics Revenue by Companies, (US$, Mn), 2017-2022
Table 7. Global Duchenne Muscular Dystrophy Therapeutics Revenue Share by Companies, 2017-2022
Table 8. Global Companies Duchenne Muscular Dystrophy Therapeutics Product Type
Table 9. List of Global Tier 1 Duchenne Muscular Dystrophy Therapeutics Companies, Revenue (US$, Mn) in 2021 and Market Share
Table 10. List of Global Tier 2 and Tier 3 Duchenne Muscular Dystrophy Therapeutics Companies, Revenue (US$, Mn) in 2021 and Market Share
Table 11. By Type – Global Duchenne Muscular Dystrophy Therapeutics Revenue, (US$, Mn), 2021 & 2028
Table 12. By Type - Duchenne Muscular Dystrophy Therapeutics Revenue in Global (US$, Mn), 2017-2022
Table 13. By Type - Duchenne Muscular Dystrophy Therapeutics Revenue in Global (US$, Mn), 2023-2028
Table 14. By Application – Global Duchenne Muscular Dystrophy Therapeutics Revenue, (US$, Mn), 2021 & 2028
Table 15. By Application - Duchenne Muscular Dystrophy Therapeutics Revenue in Global (US$, Mn), 2017-2022
Table 16. By Application - Duchenne Muscular Dystrophy Therapeutics Revenue in Global (US$, Mn), 2023-2028
Table 17. By Region – Global Duchenne Muscular Dystrophy Therapeutics Revenue, (US$, Mn), 2021 & 2028
Table 18. By Region - Global Duchenne Muscular Dystrophy Therapeutics Revenue (US$, Mn), 2017-2022
Table 19. By Region - Global Duchenne Muscular Dystrophy Therapeutics Revenue (US$, Mn), 2023-2028
Table 20. By Country - North America Duchenne Muscular Dystrophy Therapeutics Revenue, (US$, Mn), 2017-2022
Table 21. By Country - North America Duchenne Muscular Dystrophy Therapeutics Revenue, (US$, Mn), 2023-2028
Table 22. By Country - Europe Duchenne Muscular Dystrophy Therapeutics Revenue, (US$, Mn), 2017-2022
Table 23. By Country - Europe Duchenne Muscular Dystrophy Therapeutics Revenue, (US$, Mn), 2023-2028
Table 24. By Region - Asia Duchenne Muscular Dystrophy Therapeutics Revenue, (US$, Mn), 2017-2022
Table 25. By Region - Asia Duchenne Muscular Dystrophy Therapeutics Revenue, (US$, Mn), 2023-2028
Table 26. By Country - South America Duchenne Muscular Dystrophy Therapeutics Revenue, (US$, Mn), 2017-2022
Table 27. By Country - South America Duchenne Muscular Dystrophy Therapeutics Revenue, (US$, Mn), 2023-2028
Table 28. By Country - Middle East & Africa Duchenne Muscular Dystrophy Therapeutics Revenue, (US$, Mn), 2017-2022
Table 29. By Country - Middle East & Africa Duchenne Muscular Dystrophy Therapeutics Revenue, (US$, Mn), 2023-2028
Table 30. Bristol-Myers Squibb Corporate Summary
Table 31. Bristol-Myers Squibb Duchenne Muscular Dystrophy Therapeutics Product Offerings
Table 32. Bristol-Myers Squibb Duchenne Muscular Dystrophy Therapeutics Revenue (US$, Mn), (2017-2022)
Table 33. FibroGen (US) Corporate Summary
Table 34. FibroGen (US) Duchenne Muscular Dystrophy Therapeutics Product Offerings
Table 35. FibroGen (US) Duchenne Muscular Dystrophy Therapeutics Revenue (US$, Mn), (2017-2022)
Table 36. Italfarmaco (Italy) Corporate Summary
Table 37. Italfarmaco (Italy) Duchenne Muscular Dystrophy Therapeutics Product Offerings
Table 38. Italfarmaco (Italy) Duchenne Muscular Dystrophy Therapeutics Revenue (US$, Mn), (2017-2022)
Table 39. Marathon Corporate Summary
Table 40. Marathon Duchenne Muscular Dystrophy Therapeutics Product Offerings
Table 41. Marathon Duchenne Muscular Dystrophy Therapeutics Revenue (US$, Mn), (2017-2022)
Table 42. NS Pharma (US) Corporate Summary
Table 43. NS Pharma (US) Duchenne Muscular Dystrophy Therapeutics Product Offerings
Table 44. NS Pharma (US) Duchenne Muscular Dystrophy Therapeutics Revenue (US$, Mn), (2017-2022)
Table 45. PTC Therapeutics (US) Corporate Summary
Table 46. PTC Therapeutics (US) Duchenne Muscular Dystrophy Therapeutics Product Offerings
Table 47. PTC Therapeutics (US) Duchenne Muscular Dystrophy Therapeutics Revenue (US$, Mn), (2017-2022)
Table 48. Pfizer Corporate Summary
Table 49. Pfizer Duchenne Muscular Dystrophy Therapeutics Product Offerings
Table 50. Pfizer Duchenne Muscular Dystrophy Therapeutics Revenue (US$, Mn), (2017-2022)
Table 51. ReveraGen BioPharma (US) Corporate Summary
Table 52. ReveraGen BioPharma (US) Duchenne Muscular Dystrophy Therapeutics Product Offerings
Table 53. ReveraGen BioPharma (US) Duchenne Muscular Dystrophy Therapeutics Revenue (US$, Mn), (2017-2022)
Table 54. Santhera Pharmaceuticals (Switzerland) Corporate Summary
Table 55. Santhera Pharmaceuticals (Switzerland) Duchenne Muscular Dystrophy Therapeutics Product Offerings
Table 56. Santhera Pharmaceuticals (Switzerland) Duchenne Muscular Dystrophy Therapeutics Revenue (US$, Mn), (2017-2022)
Table 57. Sarepta Therapeutics (US) Corporate Summary
Table 58. Sarepta Therapeutics (US) Duchenne Muscular Dystrophy Therapeutics Product Offerings
Table 59. Sarepta Therapeutics (US) Duchenne Muscular Dystrophy Therapeutics Revenue (US$, Mn), (2017-2022)

List Of Figures

LIST OF FIGURES

Figure 1. Duchenne Muscular Dystrophy Therapeutics Segment by Type in 2021
Figure 2. Duchenne Muscular Dystrophy Therapeutics Segment by Application in 2021
Figure 3. Global Duchenne Muscular Dystrophy Therapeutics Market Overview: 2021
Figure 4. Key Caveats
Figure 5. Global Duchenne Muscular Dystrophy Therapeutics Market Size: 2021 VS 2028 (US$, Mn)
Figure 6. Global Duchenne Muscular Dystrophy Therapeutics Revenue, 2017-2028 (US$, Mn)
Figure 7. The Top 3 and 5 Players Market Share by Duchenne Muscular Dystrophy Therapeutics Revenue in 2021
Figure 8. By Type - Global Duchenne Muscular Dystrophy Therapeutics Revenue Market Share, 2017-2028
Figure 9. By Application - Global Duchenne Muscular Dystrophy Therapeutics Revenue Market Share, 2017-2028
Figure 10. By Region - Global Duchenne Muscular Dystrophy Therapeutics Revenue Market Share, 2017-2028
Figure 11. By Country - North America Duchenne Muscular Dystrophy Therapeutics Revenue Market Share, 2017-2028
Figure 12. US Duchenne Muscular Dystrophy Therapeutics Revenue, (US$, Mn), 2017-2028
Figure 13. Canada Duchenne Muscular Dystrophy Therapeutics Revenue, (US$, Mn), 2017-2028
Figure 14. Mexico Duchenne Muscular Dystrophy Therapeutics Revenue, (US$, Mn), 2017-2028
Figure 15. By Country - Europe Duchenne Muscular Dystrophy Therapeutics Revenue Market Share, 2017-2028
Figure 16. Germany Duchenne Muscular Dystrophy Therapeutics Revenue, (US$, Mn), 2017-2028
Figure 17. France Duchenne Muscular Dystrophy Therapeutics Revenue, (US$, Mn), 2017-2028
Figure 18. U.K. Duchenne Muscular Dystrophy Therapeutics Revenue, (US$, Mn), 2017-2028
Figure 19. Italy Duchenne Muscular Dystrophy Therapeutics Revenue, (US$, Mn), 2017-2028
Figure 20. Russia Duchenne Muscular Dystrophy Therapeutics Revenue, (US$, Mn), 2017-2028
Figure 21. Nordic Countries Duchenne Muscular Dystrophy Therapeutics Revenue, (US$, Mn), 2017-2028
Figure 22. Benelux Duchenne Muscular Dystrophy Therapeutics Revenue, (US$, Mn), 2017-2028
Figure 23. By Region - Asia Duchenne Muscular Dystrophy Therapeutics Revenue Market Share, 2017-2028
Figure 24. China Duchenne Muscular Dystrophy Therapeutics Revenue, (US$, Mn), 2017-2028
Figure 25. Japan Duchenne Muscular Dystrophy Therapeutics Revenue, (US$, Mn), 2017-2028
Figure 26. South Korea Duchenne Muscular Dystrophy Therapeutics Revenue, (US$, Mn), 2017-2028
Figure 27. Southeast Asia Duchenne Muscular Dystrophy Therapeutics Revenue, (US$, Mn), 2017-2028
Figure 28. India Duchenne Muscular Dystrophy Therapeutics Revenue, (US$, Mn), 2017-2028
Figure 29. By Country - South America Duchenne Muscular Dystrophy Therapeutics Revenue Market Share, 2017-2028
Figure 30. Brazil Duchenne Muscular Dystrophy Therapeutics Revenue, (US$, Mn), 2017-2028
Figure 31. Argentina Duchenne Muscular Dystrophy Therapeutics Revenue, (US$, Mn), 2017-2028
Figure 32. By Country - Middle East & Africa Duchenne Muscular Dystrophy Therapeutics Revenue Market Share, 2017-2028
Figure 33. Turkey Duchenne Muscular Dystrophy Therapeutics Revenue, (US$, Mn), 2017-2028
Figure 34. Israel Duchenne Muscular Dystrophy Therapeutics Revenue, (US$, Mn), 2017-2028
Figure 35. Saudi Arabia Duchenne Muscular Dystrophy Therapeutics Revenue, (US$, Mn), 2017-2028
Figure 36. UAE Duchenne Muscular Dystrophy Therapeutics Revenue, (US$, Mn), 2017-2028
Figure 37. Bristol-Myers Squibb Duchenne Muscular Dystrophy Therapeutics Revenue Year Over Year Growth (US$, Mn) & (2017-2022)
Figure 38. FibroGen (US) Duchenne Muscular Dystrophy Therapeutics Revenue Year Over Year Growth (US$, Mn) & (2017-2022)
Figure 39. Italfarmaco (Italy) Duchenne Muscular Dystrophy Therapeutics Revenue Year Over Year Growth (US$, Mn) & (2017-2022)
Figure 40. Marathon Duchenne Muscular Dystrophy Therapeutics Revenue Year Over Year Growth (US$, Mn) & (2017-2022)
Figure 41. NS Pharma (US) Duchenne Muscular Dystrophy Therapeutics Revenue Year Over Year Growth (US$, Mn) & (2017-2022)
Figure 42. PTC Therapeutics (US) Duchenne Muscular Dystrophy Therapeutics Revenue Year Over Year Growth (US$, Mn) & (2017-2022)
Figure 43. Pfizer Duchenne Muscular Dystrophy Therapeutics Revenue Year Over Year Growth (US$, Mn) & (2017-2022)
Figure 44. ReveraGen BioPharma (US) Duchenne Muscular Dystrophy Therapeutics Revenue Year Over Year Growth (US$, Mn) & (2017-2022)
Figure 45. Santhera Pharmaceuticals (Switzerland) Duchenne Muscular Dystrophy Therapeutics Revenue Year Over Year Growth (US$, Mn) & (2017-2022)
Figure 46. Sarepta Therapeutics (US) Duchenne Muscular Dystrophy Therapeutics Revenue Year Over Year Growth (US$, Mn) & (2017-2022)